MedTrace Logo

Recombinant Human Growth Hormone (RH-GH) For Accelerating Immune Reconstitution Post Unrelated Cord Blood Transplant

NCT00737113 · Status: TERMINATED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 14

Last updated 2014-03-20

No results posted yet for this study

Summary

The primary objective of this study is to define the safety and efficacy of recombinant human growth hormone (rh-GH, Genotropin) in a patients undergoing allogeneic transplantation.

Conditions

  • Allogeneic Stem Cell Transplantation

Interventions

DRUG

Genotropin (Recombinant Human Growth Hormone)

Patients will begin daily subcutaneous (SC) therapy at a starting dose of \~0.02mg/kg body weight. The study drug will continue for 90 days post enrollment.

Sponsors & Collaborators

  • Pfizer

    collaborator INDUSTRY

  • Mitchell Horwitz, MD

    lead OTHER

Principal Investigators

  • Mitchell Horwitz, MD · Duke University

Study Design

Allocation
NA
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
12 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2008-09-30
Primary Completion
2012-05-31
Completion
2013-12-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00737113 on ClinicalTrials.gov